Short-Term Outcomes and Immunologic Mechanisms of Adrenocorticotropic Hormone in Infantile Epileptic Spasm Syndrome: A Multicenter Prospective Trial in Southern China
Authors:
Open Access
- 27 October 2025
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (6) , 2669-2681
Abstract
Introduction Adrenocorticotropic hormone (ACTH) is a first-line drug and standard therapy in infantile epileptic spasm syndrome (IESS) with different response rates. The mechanism of ACTH for treatment of IESS remains incompletely understood. This study aimed to evaluate short-term outcomes and immunologic mechanisms of ACTH in treating pediatric patients with IESS. Methods A multicenter prospective trial of pediatric patients with IESS treated with ACTH over 2 weeks was performed. Short-term responders were defined as those with resolution of epileptic spasms and hypsarrhythmia (if present) at day 14 without epileptic spasm recurrence over 30 days after ACTH therapy, while non-responders included those with persistent spasms or hypsarrhythmia after treatment, or recurrence within 30 days. The risk factors for short-term efficacy were analyzed. The receiver operating characteristic (ROC) curve analysis was adopted to reveal the optimal critical value of peripheral blood lymphocyte subpopulations before ACTH treatment. Results Among 151 included pediatric patients, 44 (29.1%) were short-term responders. The presence of hypsarrhythmia on pre-therapy electroencephalogram (EEG) was a risk factor for the short-term efficacy (p = 0.029). A total of 81 patients accepted lymphocyte subpopulation investigation. The short-term responder group had a lower percentage of CD3+CD8+ T cells (p = 0.080) and a higher CD3+CD4+/CD3+CD8+ ratio (p = 0.077) compared to the non-responder group, but the differences were not statistically significant. ROC analysis yielded area under the curve (AUC) values of 0.599 for CD3+CD8+ T cell percentage and 0.600 for the CD3+CD4+/CD3+CD8+ratio. Patients with a CD3+CD8+ T cell percentage below 19.495% (p = 0.04) and a CD3+CD4+/CD3+CD8+ above 2.585 (p = 0.013) had a significantly higher short-term responder rate to ACTH therapy. Conclusion About 30% children with IESS were short-term responders to ACTH therapy. The presence of hypsarrhythmia on the pre-therapy EEG was a risk factor for short-term efficacy of ACTH administration. The CD3+CD8+ T cell percentage and CD3+CD4+/CD3+CD8+ ratio may exhibit a predictive capacity.Keywords
This publication has 36 references indexed in Scilit:
- Factors Influencing the Response of Patients with Infantile Epileptic Spasms Syndrome to ACTH as Repeated First-Line TherapyNeurology and Therapy, 2025
- Comparison of adrenocorticotropic hormone efficacy between aetiologies of infantile spasmsSeizure: European Journal of Epilepsy, 2021
- Infantile Spasms: Outcome in Clinical StudiesPediatric Neurology, 2020
- Etiologic classification of infantile spasms using positron emission/magnetic resonance imaging and the efficacy of adrenocorticotropic hormone therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Very-High-Dose Prednisolone Before ACTH for Treatment of Infantile Spasms: Evaluation of a Standardized ProtocolPediatric Neurology, 2019
- Oxidative Stress–Induced HMGB1 Release from Melanocytes: A Paracrine Mechanism Underlying the Cutaneous Inflammation in VitiligoJournal of Investigative Dermatology, 2019
- Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trialThe Lancet Neurology, 2017
- Response to treatment in a prospective national infantile spasms cohortAnnals of Neurology, 2015
- Peripheral lymphocyte subset and serum cytokine profiles of patients with West syndromeBrain and Development, 2010
- Corticotropin (ACTH) acts directly on amygdala neurons to down‐regulate corticotropin‐releasing hormone gene expressionAnnals of Neurology, 2001